Cushing syndrome after steroid-infiltration in two HIV-patients with antiretroviral therapy
The introduction of antiretroviral treatment with at least three active drugs has caused a substantial reduction of morbidity and mortality. Some antiretroviral drugs have the potential of interactions with other drugs. With the so called <<boosted>> protease inhibitors the cytochrom-P450 inhibition by Ritonavir is used to increase the plasma level of the protease inhibitor. This strategy results in prolonged dosage intervals and reduced tablet intake due to a reduced overall dose that is needed. The interaction potential of Ritonavir originates from this cytochrom P450-inhibition. All drugs that are CYP450-metabolized can potentially be affected. Here we report two cases that were affected by the little-known interaction of Ritonavir and Triamcinolonacetonide. In both cases, Cushing symptoms emerged after infiltrations with this steroid drug in usual doses. Here we want to emphasize on this rarely encountered but potentially serious drug-drug interaction potential that is not well known to date. When initiating any new drug in HIV-Patients under antiretroviral treatment, potential interactions should be checked. The Website www.hiv-druginteractions.org is a very useful instrument for this purpose.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Praxis - 99(2010), 14 vom: 07. Juli, Seite 863-5 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Cushing-Syndrom nach Steroid-Infiltration bei zwei behandelten HIV-infizierten Patienten |
|---|
| Beteiligte Personen: |
Herold, M A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Date Completed 02.09.2010 Date Revised 20.11.2014 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1024/1661-8157/a000190 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM199383510 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM199383510 | ||
| 003 | DE-627 | ||
| 005 | 20231223214536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1024/1661-8157/a000190 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0665.xml |
| 035 | |a (DE-627)NLM199383510 | ||
| 035 | |a (NLM)20607670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Herold, M A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cushing syndrome after steroid-infiltration in two HIV-patients with antiretroviral therapy |
| 246 | 3 | 3 | |a Cushing-Syndrom nach Steroid-Infiltration bei zwei behandelten HIV-infizierten Patienten |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2010 | ||
| 500 | |a Date Revised 20.11.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The introduction of antiretroviral treatment with at least three active drugs has caused a substantial reduction of morbidity and mortality. Some antiretroviral drugs have the potential of interactions with other drugs. With the so called <<boosted>> protease inhibitors the cytochrom-P450 inhibition by Ritonavir is used to increase the plasma level of the protease inhibitor. This strategy results in prolonged dosage intervals and reduced tablet intake due to a reduced overall dose that is needed. The interaction potential of Ritonavir originates from this cytochrom P450-inhibition. All drugs that are CYP450-metabolized can potentially be affected. Here we report two cases that were affected by the little-known interaction of Ritonavir and Triamcinolonacetonide. In both cases, Cushing symptoms emerged after infiltrations with this steroid drug in usual doses. Here we want to emphasize on this rarely encountered but potentially serious drug-drug interaction potential that is not well known to date. When initiating any new drug in HIV-Patients under antiretroviral treatment, potential interactions should be checked. The Website www.hiv-druginteractions.org is a very useful instrument for this purpose | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Triamcinolone Acetonide |2 NLM | |
| 650 | 7 | |a F446C597KA |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Hydrocortisone |2 NLM | |
| 650 | 7 | |a WI4X0X7BPJ |2 NLM | |
| 700 | 1 | |a Günthard, H F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Praxis |d 1994 |g 99(2010), 14 vom: 07. Juli, Seite 863-5 |w (DE-627)NLM074578928 |x 1661-8157 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2010 |g number:14 |g day:07 |g month:07 |g pages:863-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1024/1661-8157/a000190 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2010 |e 14 |b 07 |c 07 |h 863-5 | ||